- Home
- COGT vs TRVI Comparison
COGT vs TRVI Comparison
Compare COGT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- TRVI
- Stock Information
- Founded
- COGT 2014
- TRVI 2011
- Country
- COGT United States
- TRVI United States
- Employees
- COGT N/A
- TRVI N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- COGT Health Care
- TRVI Health Care
- Exchange
- COGT Nasdaq
- TRVI Nasdaq
- Market Cap
- COGT 1.1B
- TRVI 1.1B
- IPO Year
- COGT 2018
- TRVI 2019
- Fundamental
- Price
- COGT $16.19
- TRVI $9.89
- Analyst Decision
- COGT Strong Buy
- TRVI Strong Buy
- Analyst Count
- COGT 11
- TRVI 9
- Target Price
- COGT $21.20
- TRVI $20.72
- AVG Volume (30 Days)
- COGT 1.9M
- TRVI 2.1M
- Earning Date
- COGT 11-11-2025
- TRVI 11-05-2025
- Dividend Yield
- COGT N/A
- TRVI N/A
- EPS Growth
- COGT N/A
- TRVI N/A
- EPS
- COGT N/A
- TRVI N/A
- Revenue
- COGT N/A
- TRVI N/A
- Revenue This Year
- COGT N/A
- TRVI N/A
- Revenue Next Year
- COGT N/A
- TRVI N/A
- P/E Ratio
- COGT N/A
- TRVI N/A
- Revenue Growth
- COGT N/A
- TRVI N/A
- 52 Week Low
- COGT $3.72
- TRVI $2.36
- 52 Week High
- COGT $16.46
- TRVI $10.16
- Technical
- Relative Strength Index (RSI)
- COGT 74.84
- TRVI 67.19
- Support Level
- COGT $15.26
- TRVI $9.30
- Resistance Level
- COGT $16.22
- TRVI $10.16
- Average True Range (ATR)
- COGT 0.71
- TRVI 0.49
- MACD
- COGT 0.21
- TRVI 0.08
- Stochastic Oscillator
- COGT 92.27
- TRVI 90.80
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.